BG98933A - Охладен и пулверизиран набуметон - Google Patents

Охладен и пулверизиран набуметон

Info

Publication number
BG98933A
BG98933A BG98933A BG9893394A BG98933A BG 98933 A BG98933 A BG 98933A BG 98933 A BG98933 A BG 98933A BG 9893394 A BG9893394 A BG 9893394A BG 98933 A BG98933 A BG 98933A
Authority
BG
Bulgaria
Prior art keywords
nabumetone
atomized
cooled
far
produced
Prior art date
Application number
BG98933A
Other languages
English (en)
Inventor
Graham LEONARD
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG98933A publication Critical patent/BG98933A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coating By Spraying Or Casting (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Freezing, Cooling And Drying Of Foods (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Road Signs Or Road Markings (AREA)
  • Catching Or Destruction (AREA)

Abstract

Набуметонът е приложим в химикофармацевтичната промишленост. Изобретението се отнася също и до форми, приготвени като единични дози, които са с по-малък обем от постигнатия досега.
BG98933A 1992-01-29 1994-07-28 Охладен и пулверизиран набуметон BG98933A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929201857A GB9201857D0 (en) 1992-01-29 1992-01-29 Novel compound
PCT/GB1993/000145 WO1993014747A1 (en) 1992-01-29 1993-01-22 Spray-chilled nabumetone

Publications (1)

Publication Number Publication Date
BG98933A true BG98933A (bg) 1995-07-28

Family

ID=10709436

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98933A BG98933A (bg) 1992-01-29 1994-07-28 Охладен и пулверизиран набуметон

Country Status (24)

Country Link
US (1) US5539000A (bg)
EP (1) EP0624087B1 (bg)
JP (1) JPH07503245A (bg)
KR (1) KR950700056A (bg)
CN (1) CN1079954A (bg)
AT (1) ATE150298T1 (bg)
AU (1) AU3362693A (bg)
BG (1) BG98933A (bg)
BR (1) BR9305674A (bg)
CA (1) CA2129027A1 (bg)
CZ (1) CZ182894A3 (bg)
DE (1) DE69309037T2 (bg)
DK (1) DK0624087T3 (bg)
ES (1) ES2099419T3 (bg)
FI (1) FI943550A0 (bg)
GB (1) GB9201857D0 (bg)
GR (1) GR3023142T3 (bg)
HU (1) HUT67462A (bg)
IL (1) IL104526A0 (bg)
MX (1) MX9300430A (bg)
NO (1) NO942813L (bg)
SK (1) SK91694A3 (bg)
WO (1) WO1993014747A1 (bg)
ZA (1) ZA93577B (bg)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US20020132010A1 (en) * 2000-12-22 2002-09-19 Yihong Qui Divalproex sodium dosage forms and a process for their production
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) * 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
EP1691787B1 (en) * 2003-12-04 2008-07-02 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
RU2006119453A (ru) * 2003-12-04 2007-12-20 Пфайзер Продактс Инк. (Us) Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053653A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
WO2006044657A2 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
CA2619643A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) * 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
KR101940207B1 (ko) 2010-05-12 2019-01-18 스펙트럼 파마슈티컬즈 인크 란탄 카보네이트 하이드록사이드, 란탄 옥시카보네이트 및 이들의 제조 및 사용 방법
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420639C1 (en) * 1973-09-11 2001-08-21 Beecham Group Ltd Aromatic compounds
GB1474377A (en) 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives
US4086346A (en) 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
DE3833446A1 (de) 1988-10-01 1990-04-05 Hoechst Ag Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten

Also Published As

Publication number Publication date
ATE150298T1 (de) 1997-04-15
ES2099419T3 (es) 1997-05-16
FI943550A (fi) 1994-07-28
NO942813D0 (no) 1994-07-28
US5539000A (en) 1996-07-23
JPH07503245A (ja) 1995-04-06
DK0624087T3 (da) 1997-09-01
HU9402221D0 (en) 1994-09-28
FI943550A0 (fi) 1994-07-28
NO942813L (no) 1994-07-28
ZA93577B (en) 1994-01-13
DE69309037D1 (de) 1997-04-24
IL104526A0 (en) 1993-05-13
HUT67462A (en) 1995-04-28
SK91694A3 (en) 1995-03-08
GB9201857D0 (en) 1992-03-18
EP0624087B1 (en) 1997-03-19
BR9305674A (pt) 2005-01-11
WO1993014747A1 (en) 1993-08-05
CN1079954A (zh) 1993-12-29
EP0624087A1 (en) 1994-11-17
DE69309037T2 (de) 1997-07-24
CZ182894A3 (en) 1995-02-15
KR950700056A (ko) 1995-01-16
MX9300430A (es) 1994-08-31
CA2129027A1 (en) 1993-08-05
AU3362693A (en) 1993-09-01
GR3023142T3 (en) 1997-07-30

Similar Documents

Publication Publication Date Title
BG98933A (bg) Охладен и пулверизиран набуметон
EP0494972A4 (en) Effervescent dosage form and method of administering same
TW272195B (bg)
CZ44195A3 (en) Pharmaceutical preparation containing il-4 and/or il-10 or antibodies against il-4 and il-10, process of its preparation and use
GEP20074251B (en) N-oxycarbonyl substituted 5'- deoxy-5-fluorocytidines
MY102365A (en) Di-t-butylphenol compounds.
HU9403323D0 (en) 4-mercaptioacetylamino-[2] benzazepinone(3) derivatives, and use as enkephalinase inhibitors
HK1002017A1 (en) Lyospheres comprising gonadotropin
GR3023541T3 (en) N,O-sulfated heparosanes; process to produce the same and pharmaceutical compositions containing them
ES2191174T3 (es) (-)hidroxicitrato de magnesio, procedimiento de preparacion, aplicaciones y composiciones principalmente farmaceuticas que lo contienen.
MY109990A (en) Microfluidised particles of atovaquone and pharmaceutical preparation thereof
EG18379A (en) Novel pharmacological compounds
IL102337A0 (en) Pyrrolpyrazines,their manufacture and pharmaceutical compositions containing them
IL104999A0 (en) Substituted phenylacetamides,their preparation and pharmaceutical compositions containing them
IL110809A0 (en) 1,5-diphenyl-3-pyrazolylalkyl-n-hydroxydithiocarbamates and pharmaceutical compositions containing them
IL105000A0 (en) Imidazolyl-substituted phenylacetamides,their preparation and pharmaceutical compositions containing them
BG100248A (bg) Инхибитори на скваленсинтетаза
EP0461261A4 (en) MIXTURE OF OLIGOPEPTIDES AND PREPARATION CONTAINING SAME.
MD970269A (en) Clavulanates
IL104418A0 (en) Disubstituted polycyclic compounds and pharmaceutical compositions containing them
HUT65768A (en) 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them and process for the production thereof
IL110780A0 (en) Pharmaceutical compositions containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol for the treatment of the common cold
TW218011B (bg)
IT1199619B (it) Vernici additivate
GB2252729B (en) Vitamin and/or mineral containing pharmaceutical compositions